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Abstract
Venous thromboembolus is an important cause of hospital acquired morbidity and mortality. Venous
thrombosis is a very rare occurrence in patients with haemophilia A. The thrombosis originated from
the right main and external iliac veins, and effects the cranial segments of the main, deep and
superficial femoral veins as an acute phase thrombus. Neither any local anatomic compression nor
any predisposing thrombophilic risk factors were identified. We treated the patient with enoxaparine
1 mg/kg twice a day subcutaneously and then started oral anticoagulation with warfarin.
Introduction
Venous thromboembolus is an important cause of hospital
acquired morbidity and mortality [1]. Hemophilia A is
a hereditary hemorrhagic disease characterized by defi-
ciency of coagulation Factor VIII. Venous thrombosis has
been rarely encountered among patients with hemophilia
A [2,3]. Despite the underlying hematological disorders,
the development of thrombotic events has been rarely
reported in the literature [2,4-7]. In this case report we
present the onset of deep vein thrombosis in a 32-year-old
male patient with hemophilia A.
Case presentation
The history of a 32-year-oldwhitemale patient that had the
diagnosis of hemophilia has revealed two surgeries due to
intracapsular hemorrhage of right knee joint anda subdural
hematoma. The patient had taken his last Factor VIII
replacement 3months before, and had complaints of pain,
edema and warmth on the right lower extremity for two
days. On physical examination, his right lower extremity
was warmer and 2 cm larger than the left lower extremity in
circumference. According to the visual analog scale, the
pain score was 6.
At Doppler ultrasonography, originating from the right
main and external iliac veins, traversing up to cranial
segments of the main, deep and superficial femoral veins
an acute phase thrombus was found, without any response
to augmentation (Figure 1A). Activated partial thrombo-
plastin time, bleeding time and prothrombin time are
given in Table 1. The level of Factor VIII was lower than
2% of normal value.
Patient was treated with enoxaparine 1 mg/kg twice a day
and oral warfarin was started 2 days. After achieving an
international normalization ratio of 2.0 we stopped giving
low molecular weight heparin. Daily coagulation tests and
monitorization of thrombocyte levels were performed.
The complaints were markedly reduced within the first
week of treatment, so the patient was discharged. Doppler
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ultrasonography was performed at the end of the 6th week
and no thrombus was found; a response to augmentation
was visible by color Doppler (Figure 1B).
Discussion
Venous thrombosis is an important cause of hospital
acquired morbidity and mortality [1]. Thrombosis is rarely
encountered among patients with hemophilia A [2,4].
A total of 12 cases have been reported in the literature, 5 of
them regarding deep venous thrombosis [3]. There has
been no description of cases with normal coagulation test
results and absence of any factor replacement treatment
for at least one month which spontaneously developed
deep venous thrombosis on the lower extremity.
The most important risk factor for patients with hemo-
philia A is taking Factor VIII inhibitor bypassing activity
(FEIBA) or recombinant activated factor VII (rFVIIa) for
inhibitors; however, Factor VII or Factor IX concentrations
are also important [3]. Other risk factors can be listed as
congenital prothrombotic condition in heterozygote level,
deficiency of protein C and Factor V Leiden [8]. In addition
to these, Kashyap et al. have shown that FII G20210A
mutation is another risk factor [8].
Replacement therapy in patients with hemophilia
A reduces the thrombophilia development to ratings
close to the normal population’s [9,10]. Van der Planken
reported a deep venous thrombosis development within
18 days after recombinent activated factor VII (rFVIIa)
infusion in a 38 years old patient with hemophilia A [11].
Ettingshausen et al. described portal venous thrombosis in
a patient with the diagnosis of hemophilia A and Factor V
G1691A mutation during continuous Factor VIII infusion
after jejunal bleeding [6]. Mahmoud et al. reported a fatal
systemic venous thrombosis resulted from Factor VIIa
infusion, which was administered for bleeding control
after cardiac surgery [12].
The subjects with methylenetetrahydrofolate reductase
(MTHFR) gene polimorphysm have a predisposition to
hyperhomocystinemia. In previous studies, a tendency to
venous and arterial thrombosis was identified in normal
subjects who developed hyperhomocystinemia [13,14].
Although the efficacy of Factor V Leiden was at issue, when
it was applied in FII G20210A mutation, the thrombosis
formation tendency increased [15]. In this case, because
neither a prothrombotic disposition via laboratory tests
nor other gene polymorphisms were detected, the presence
of homozygote mutation in MTHFR gene made us
consider its contribution to the development of throm-
bosis in our patient. This situation as well suggested that
MTHFR gene polymorphism itself may cause a prothrom-
botic disposition.
The treatment of venous thrombosis in patients diagnosed
with thrombotic disorders such as hemophilia A lacks
clear information because of the low number of cases.
Dargaud et al. have used unfractioned heparin for a month
subsequent to Factor VIII replacement [2]; Kashyap et al.
have administered low molecular weight heparin for
9 weeks [8]; Ettinsghausen et al. have applied low
molecular weight heparin together with Factor VIII
replacement, after unfractioned heparin for 14 days. The
oral anticoagulant drugs were not a preference since they
increase hemorrhage risk.
In our case, the administration of oral anticoagulant drug
was initiated after 48 hours, because coagulation tests were
normal, Factor V Leiden and prothrombin G20210A
Figure 1. (A) Doppler ultrasonography showing an acute
phase thrombus without any response to augmentation.
(B) Restored flow and disappearence of the thrombus
after therapy.
Table 1. Laboratory tests results
Test Patient’s result Normal value
Platelet count (×109 L−1) 320 142.2-424.0
Bleeding time 1 min 1-5 min
PT (s) 15 10-15
PA (%) 73.9 70-130
APTT (sec) 80.1 20-31
INR 1.2 0.9-1.2
Factor VIII level (%) 2 70-150
Protein S (activity; %) 41.9 70-123
Protein C (activity; %) 111.2 70-140
Antithrombin III (%) 97.1 75-125
Fibrinogen (g/L) 6.6 1.8-3.5
Lupus anticoagulant 0.98 1-1.3
Anticardiolipin antibodies Negative
Factor V Leiden Negative
Prothrombin G20210A Negative
MTHFR C677T Homozygote mutation
APC resistance Absent
PT, prothrombin time; PA, prothrombin activity; APTT, activated partial
thromboplastin time; INR, international normalization ratio; APC, acti-
vated protein C; MTHFR, methylenetetrahydrofolate reductase.
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mutation were absent, Factor VIII levels were replaced
during patient’s follow-up, and there was a lack of proteins
C and S, which could cause thrombosis in an early phase.
This patient was monitored through daily coagulation
tests, and marked improvement was observed in his
clinical features by color doppler ultrasonography after
6 weeks of treatment. Since these cases are rare, there is no
consensus on the therapy; nevertheless, we have been
considering oral anticoagulants to be used as treatment,
although it requires close monitoring for hemorrhage in
these patients.
Conclusion
Hemophilia A is a hereditary hemorrhagic disorder
characterized by Factor VIII’s deficiency. Severe Factor
VIII deficiency can cause bleeding within the joint, soft
tissue and muscle. Arterial and venous thrombosis rarely
occur and form a paradox to the underlying disease.
Unclearity of the venous thrombosis’ mechanism leads to
testing alternative treatments. Therefore, it is necessary that
the mechanism and treatment of thrombosis be further
investigated.
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